Preclinical evaluation of a new 18F-labled probe as a potent PET imaging ligand for GluN2B subunit in NMDA receptors

Conclusions: [18F]1 showed high selective and specific binding to GluN2B subunit in in vitro ARG with brain sections of both rat and NHP, which could be preciously blocked by compound 1 itself and BMT-108908. Furthermore, [18F]1 possessed good capability of BBB penetration and fast washout rate from the mice brain. These results suggested that [18F]1 had great potential utility in PET imaging of GluN2B subunit. Acknowledgments: We thank Drs. Thomas Brady (Nuclear Medicine, MGH) for his helpful discussion. References: 1. Mony L et al. Br. J. Pharmacol. 2009;157:1301-1317.2. Marcin LR et al. ACS Med. Chem. Lett. 2018;9:472-477.3. Monyer H et al.. Neuron. 1994;12:529-540.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Fu, H., Shao, T., Chen, Z., Shao, Y., Sun, S., Josephson, L., Wey, H.-Y., Daunais, J., Li, Z., Liang, S. Tags: Preclinical Probes for Neuroimaging Posters Source Type: research